重组人血管内皮抑素联合NP方案治疗初诊晚期非小细胞肺癌骨转移疗效及对血清VEGF表达的影响

Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diagnosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF

目的探讨重组人血管内皮抑素联合长春瑞滨+顺铂(NP)化疗对初诊晚期非小细胞肺癌骨转移患者的疗效和血清血管内皮生长因子的影响。方法于2009年1月—2012年1月间收治的初诊晚期非小细胞肺癌骨转移患者40例,随机分为治疗组(20例)和对照组(20例),对照组予以单纯NP化疗,治疗组予以重组人血管内皮抑素联合NP化疗,比较两组的临床疗效和治疗前后血清血管内皮生长因子的变化。结果经过两周期全身化疗后,治疗组的客观缓解率和疾病控制率分别为30.0%和80.0%,对照组分别为5.0%和45.0%,治疗组的客观缓解率和疾病控制率均显著高于对照组(P<0.05)。两组治疗前后血清血管内皮生长因子的变化无统计学意义(P>0.05)。两组患者的不良反应发生率无统计学差异(P>0.05)。结论重组人血管内皮抑素联合NP方案可提高初诊晚期非小细胞肺癌骨转移患者治疗效果,且不会增加不良反应的发生率,但是血清血管内皮生长因子变化不明显。

Objective To explore the efficacy of recombinant human endostatin（Rh- endostatin） combined with vinorelbine- cisplatin（NP） regimen for newly diagnosed patients with advanced non — small cell lung cancer（NSCLC） with bone metastases and the impact on expression of serum vascular endothelial growth factor（VEGF）.Methods From January 1,2009 to February 1,2012,a total of 40 with newly diagnosed,advanced NSCLC patients with bone metastases were enrolled in this study and randomly assigned to the treatment（N = 20）or control（N = 20） group.The control group was only given the NP regimen chemotherapy and the treatment group was treated with Rh- endostatin combined with NP regimen.The changes in clinical effects of the two groups and serum VEGF levels were observed.Results After two cycles of systemic chemotherapy,objective response rate（ORR）and disease control rate（DCR） of the treatment group were 30.0%and 80.0%significantly higher than5.0%and 45.0%of the control group（P〈0.05）.Serum VEGF Level did not significantly change before and after treatments in the two groups（P〉0.05）.Conclusion Rh- endostatin combined with NP regimen can improve the efficiency of treatment for newly diagnosed patients with advanced NSCLC with bone metastases and does not increase adverse reactions whereas no significant difference in serum VEGF Levels.